Cardiff Oncology Statistics Share Statistics Cardiff Oncology has 66.53M
shares outstanding. The number of shares has increased by 42.91%
in one year.
Shares Outstanding 66.53M Shares Change (YoY) 42.91% Shares Change (QoQ) 0% Owned by Institutions (%) 48.62% Shares Floating 60.47M Failed to Deliver (FTD) Shares 33,357 FTD / Avg. Volume 1.8%
Short Selling Information The latest short interest is 18.9M, so 28.4% of the outstanding
shares have been sold short.
Short Interest 18.9M Short % of Shares Out 28.4% Short % of Float 29.16% Short Ratio (days to cover) 14.23
Valuation Ratios The PE ratio is -4.55 and the forward
PE ratio is -2.74.
Cardiff Oncology's PEG ratio is
-2.12.
PE Ratio -4.55 Forward PE -2.74 PS Ratio 302.78 Forward PS 471.5 PB Ratio 2.49 P/FCF Ratio -5.47 PEG Ratio -2.12
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cardiff Oncology.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.08,
with a Debt / Equity ratio of 0.02.
Current Ratio 7.08 Quick Ratio 7.08 Debt / Equity 0.02 Debt / EBITDA -0.03 Debt / FCF -0.04 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $21.34K Profits Per Employee $-1.42M Employee Count 32 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax -24K Effective Tax Rate 0.05%
Stock Price Statistics The stock price has increased by 3.1% in the
last 52 weeks. The beta is 1.54, so Cardiff Oncology's
price volatility has been higher than the market average.
Beta 1.54 52-Week Price Change 3.1% 50-Day Moving Average 3.52 200-Day Moving Average 3.44 Relative Strength Index (RSI) 32.39 Average Volume (20 Days) 1,857,325
Income Statement In the last 12 months, Cardiff Oncology had revenue of 683K
and earned -45.43M
in profits. Earnings per share was -0.95.
Revenue 683K Gross Profit 683K Operating Income -48.65M Net Income -45.43M EBITDA -48.25M EBIT -48.65M Earnings Per Share (EPS) -0.95
Full Income Statement Balance Sheet The company has 51.47M in cash and 1.52M in
debt, giving a net cash position of 49.95M.
Cash & Cash Equivalents 51.47M Total Debt 1.52M Net Cash 49.95M Retained Earnings -384.18M Total Assets 75.74M Working Capital 57.03M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -37.69M
and capital expenditures -80K, giving a free cash flow of -37.77M.
Operating Cash Flow -37.69M Capital Expenditures -80K Free Cash Flow -37.77M FCF Per Share -0.79
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -7123.13% and -6651.68%.
Gross Margin 100% Operating Margin -7123.13% Pretax Margin -6655.2% Profit Margin -6651.68% EBITDA Margin -7063.98% EBIT Margin -7123.13% FCF Margin -5530.45%
Dividends & Yields CRDF does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CRDF is $10,
which is 329.2% higher than the current price. The consensus rating is "Buy".
Price Target $10 Price Target Difference 329.2% Analyst Consensus Buy Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Feb 20, 2019. It was a
backward
split with a ratio of 1:6.
Last Split Date Feb 20, 2019 Split Type backward Split Ratio 1:6
Scores Altman Z-Score -3.45 Piotroski F-Score 1
